FIELD: medicine.
SUBSTANCE: present invention refers to remedies and namely to anti-HIV combination and composition including (i) Tenofovir or its disoproxylfumarate derivate, (ii) Ritonavir and (iii) TMC114, which can be used for treatment or preventive treatment of HIV infection. Besides invention refers to the use of the above combination and treatment method of human HIV infection.
EFFECT: such combination of active components leads to the improved disposition profile.
14 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING HIV-INFECTION, METHOD FOR PREPARING AND METHOD OF USING | 2013 |
|
RU2543322C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING HIV INFECTION, METHOD FOR PREPARING IT, AND METHOD OF TREATING | 2012 |
|
RU2505286C1 |
| ATAZANAVIR APPLICATION IN HIV INFECTION THERAPY | 2002 |
|
RU2316341C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
| AZAPEPTIDE DERIVATIVES | 2008 |
|
RU2448958C2 |
| COMBINATION OF CYTOCHROME-P450-DEPENDENT PROTEASE INHIBITORS | 2002 |
|
RU2329050C2 |
| NEW ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2508105C2 |
| METHOD OF TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE | 2020 |
|
RU2840867C1 |
| PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
| PHARMACEUTICAL COMPOSITION HAVING ANTI-HIV INFECTION ACTIVITY | 2017 |
|
RU2659693C1 |
